A Study of BMS-986490 With or Without Bevacizumab in Advanced Solid Tumors

Launched by BRISTOL-MYERS SQUIBB · Dec 9, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment called BMS-986490, both on its own and in combination with another drug called bevacizumab, for people with advanced solid tumors. These tumors are types of cancer that cannot be removed through surgery and may have spread to other parts of the body. Specifically, the study is looking at patients whose tumors express a protein known as CEACAM5. The trial is currently recruiting participants aged 65 to 74, and it is open to individuals of any gender.

To be eligible for this trial, participants need to have specific types of advanced cancer, such as colorectal cancer, non-small cell lung cancer, or gastric cancer, and their disease must have worsened despite previous treatments. Participants will be monitored closely during the study to see how well the treatment works and to check for any side effects. It’s important for potential participants to know that they cannot have a history of severe allergic reactions to the study drugs or have previously received certain targeted therapies. Overall, this trial aims to explore new options for patients with limited treatment choices, and participants will play a vital role in advancing cancer research.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Documented histologically or cytologically confirmed, advanced, unresectable/metastatic solid tumor measurable by RECIST v1.1.
• • CRC: Part 1A, Part 2A-CRC, Part 1B, and Part 2B:.
• • i) Locally advanced/metastatic, recurrent, or unresectable CRC with adenocarcinoma histology and whose disease has progressed after systemic cancer therapy in the metastatic or adjuvant setting including 5-FU, irinotecan, and/or oxaliplatin (if available and not contraindicated).
• • NSCLC: Part 2A-NSCLC/GC, 3L+ NSCLC:.
• • i) Histologically confirmed NSCLC meeting stage criteria for Stage IIIB, Stage IV, or recurrent disease.
• • ii) Progressed on at least 2 prior lines of therapy,
• • iii) Participants must have received and progressed on or after anti-PD-(L)1 therapy, if available.
• • - GC: Part 2A-NSCLC/GC, 2L+ GC:.
• • i) Participants must have received and then progressed or been intolerant to at least 1 standard treatment regimen in the advanced or metastatic setting (or have progressed within 6 months of adjuvant therapy).
• • ii) ECOG performance status of 0 or 1.
• Exclusion Criteria:
• • History of anaphylactic reactions to irinotecan and/or bevacizumab.
• • Previously received therapy targeting CEACAM5.
• • Grade ≥ 3 ILD/pneumonitis.
• • Other protocol-defined Inclusion/Exclusion criteria apply.